J
Jessica Hardin
Researcher at East Carolina University
Publications - 6
Citations - 235
Jessica Hardin is an academic researcher from East Carolina University. The author has contributed to research in topics: Tocilizumab & Immune checkpoint. The author has an hindex of 3, co-authored 6 publications receiving 145 citations.
Papers
More filters
Journal ArticleDOI
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade.
Chipman Rg Stroud,Aparna Madhukeshwar Hegde,Cynthia R. Cherry,Abdul Rafeh Naqash,Nitika Sharma,Srikala Addepalli,Sulochana Devi Cherukuri,Teresa Parent,Jessica Hardin,Paul R. Walker +9 more
TL;DR: Tocilizumab may be a therapeutic option for the management of steroid refractory irAEs secondary to immune checkpoint blockade, however, randomized trials are needed to better elucidate the relative efficacy and safety of these agents.
Journal ArticleDOI
Systemic inflammatory response syndrome (SIRS) with immune checkpoint inhibitors.
Nitika Sharma,Chipman Robert Geoffrey Stroud,Paul R. Walker,Cynthia R. Cherry,Sulochana Devi Cherukuri,Srikala Addepalli,Teresa Parent,Jessica Hardin +7 more
TL;DR: This data indicates that suppression of immune checkpoint blockade through EMT alone or a combination of EMT and chemotherapy is an attractive treatment option in a wide spectrum of malignancies.
Journal ArticleDOI
OA03.05 Tocilizumab for the Management of Immune Mediated Adverse Events Secondary to PD-1 Blockade: Overall Survival Analysis: Topic: Medical Oncology
Chipman Robert Geoffrey Stroud,Aparna Madhukeshwar Hegde,Abdul Rafeh Naqash,Cynthia R. Cherry,Teresa Parent,Jessica Hardin,Paul R. Walker +6 more
Journal ArticleDOI
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade.
Chipman Robert Geoffrey Stroud,Cynthia R. Cherry,Abdul Rafeh Naqash,Nitika Sharma,Sulochana Devi Cherukuri,Teresa Parent,Jessica Hardin,Paul R. Walker +7 more
TL;DR: The once-weekly treatment of steroid-refractory immune mediated central giant cell granuloma with or without chemotherapy is indicated to be a viable treatment option for these patients with atypical immune checkpoint disorders.
Journal ArticleDOI
Outcomes with immune checkpoint inhibitor use in lung cancer patients with hepatic metastases.
Srikala Addepalli,Chipman Robert Geoffrey Stroud,Sulochana Devi Cherukuri,Cynthia R. Cherry,Nitika Sharma,Teresa Parent,Jessica Hardin,Paul R. Walker +7 more
TL;DR: A retrospective analysis of the lung cancer patients treated at East Carolina University with the PD1 inhibitor Nivolumab to evaluate predictive markers of response to immune checkpoint blockade found that efficacy appears to be variable based on the site of disease.